Quidel to Participate in the CEO Series Conference Call Hosted by Canaccord Genuity

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will participate in the CEO Series Conference Call, hosted by Canaccord Genuity on Monday, September 11, 2017 at 11:00 a.m. Eastern time (8:00 a.m. Pacific time).

During the presentation, the company will discuss business and financial developments and trends, which may include discussion of the Company’s pending acquisition of assets of the Triage® MeterPro cardiovascular and toxicology business, and the Triage BNP business from Alere Inc. The company's statements may contain or constitute material information that has not been previously disclosed.

The conference call may be accessed by dialing [phone] for participants in the U.S./Canada or [phone] for participants outside the U.S./Canada using the required conference ID 83358293. A live webcast and audio archive of the conference call will be available via the Investor Relations section of the company’s Web site at http://ir.quidel.com

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct Detection, Thyretain® and InflammaDry® leading brand names, as well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel’s research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians’ offices and hospital and reference laboratories. For more information about Quidel’s comprehensive product portfolio, visit quidel.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170908005445/en/

For Quidel CorporationRandy StewardChief Financial Officer(858) 552-7931orVictoria SivraisClermont Partners(312) [e-mail]